Phase II Trial

• Business
• Education
• Financial
• Germany
• Healthcare
• Industrial
• Investment
• Management
• News
• Pharma & Biotech
• Science
• Technology

Boehringer Ingelheim’s Survodutide Shows Promising Results as Potential Best-in-Class Treatment for MASH in Phase II Trial

(IN BRIEF) Boehringer Ingelheim has reported compelling results from its Phase II trial of Survodutide, a novel glucagon/GLP-1 receptor dual…